Virpax Pharmaceuticals (VRPX) late Tuesday reported positive results from a dose range finding study of its Probudur pain relief treatment in beagle dogs, further paving the way for its investigational new drug application.
The study assessed the tolerance of Probudur when administered by subcutaneous injection in a dose-escalating manner. The company said all the dogs in the study showed positive tolerance to Probudur, with no adverse effects.
Study results indicate that doses of LBL100 up to 90 mg/kg are "well tolerated" by beagle dogs, Virpax said.
Its shares were up 36% in recent premarket activity Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments